Dexcom, Inc., a prominent player in the health care sector, specializing in health care equipment and supplies, has recently filed a Form 144 with the U.S. Securities and Exchange Commission (SEC). This filing, dated August 20, 2026, pertains to the sale of a block of common shares by an officer and director of the company, Kevin R. Sayer. The transaction involves approximately 26,700 shares, with the sale expected to close on the same day of filing.
Dexcom, Inc. is renowned for its innovative continuous glucose monitoring systems, designed to aid individuals managing diabetes. The company’s flagship product is a small implantable device that measures glucose levels in subcutaneous tissue, paired with an external receiver that transmits glucose data at specified intervals. This technology has positioned Dexcom as a leader in the health care equipment and supplies industry.
The Form 144 filing provides detailed information about the transaction, including the broker handling the sale, the acquisition date of the shares, and recent sales activity by Kevin R. Sayer in the preceding months. The filing confirms that the shares are being sold under a plan adopted by the company earlier in the year. Standard information such as the issuer’s address and contact details are also included in the filing.
As of August 20, 2026, Dexcom’s stock closed at $92.34, with a 52-week high of $92.56 and a 52-week low of $54.11, recorded on November 6, 2025. The company’s market capitalization stands at approximately $34.85 billion, with a price-to-earnings ratio of 36.2. Dexcom’s primary exchange is Nasdaq, and its financial transactions are conducted in USD.
The filing does not include any additional disclosures beyond the sale of shares, nor does it encompass further corporate actions or financial statements. This transaction is part of the company’s ongoing strategy and governance practices, reflecting the typical activities of its officers and directors in managing their equity holdings.
Dexcom, Inc. continues to focus on its core mission of developing advanced medical devices to improve the quality of life for individuals with diabetes, maintaining its position as a key innovator in the health care sector.
